Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Lupin and Boehringer Ingelheim announce Partnership to Develop and Commercialize Novel Oncology Drug to treat KRAS-driven Cancers

Posted On: 2019-09-04 14:10:09

Boehringer Ingelheim and Lupin Limited (Lupin) have announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin's lead MEK inhibitor compound in combination with one of Boehringer Ingelheim's innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.

Commenting on the partnership, Nilesh Gupta, Managing Director, Lupin Limited said, "With the success of our second new drug discovery program in oncology, we have made a significant mark in bringing novel treatments to patients. Lupin's MEK Inhibitor program successfully cleared early clinical stages, demonstrating our capabilities in delivering world class innovation. We are proud of the achievements of our team and the capabilities we have built which enable us to further our new drug discovery program. We are delighted to partner with Boehringer Ingelheim in developing treatments that w ill truly benefit patients in need".

Dr. Raj Kamboj, President of Lupin's Novel Drug Discovery and Development (NDDD) stated, "The success of our second NDDD program in Oncology has added to our confidence in bringing highly differentiated and best-in-class innovation from India for patients globally. Carrying forward our founder, Dr. Desh Bandhu Gupta's dream in shaping true innovation, we have delivered a novel treatment from conceptualization to clinical stage development with promising results that can be a potential combination treatment for precision oncology."

"The licensing of Lupin's novel MEK inhibitor enables us to pair with our innovative KRAS inhibitors to develop new combination treatment concepts providing more effect ive and durable responses for patients with cancers driven by activated KRAS who currently have limited treatment options available," said Norbert Kraut, Ph.D., Head of Global Cancer Research at Boehringer Ingelheim. "We believe this collaboration will significantly strengthen our KRAS program. We have developed comprehensive approaches to successfully tackle the oncogenic KRAS - RAF - MEK - ERK pathway from the ground up and this partnership is another key building block in our long-term strategy to bring novel treatments to patients in our quest to defeat intractable cancer types."

The collaboration has a strategic goal to focus on patients with gastrointestinal or lung cancers defined by KRAS mutations, sub-populations that currently need more effective therapeutic options. KRAS mutations occur in 1 in 7 of all human metastatic cancers making it the most frequently mutated cancer-causing gene, with mutation rates of more than 90 perce nt in pancreatic cancers, more than 40 percent in colorectal cancers and more than 30 percent in lung adenocarcinomas. Preclinical data has shown that the combination of Boehringer Ingelheim's novel KRAS inhibitors with MEK inhibitors results in increased anti-tumor activity based on their complementary mechanisms of action in keeping KRAS-driven cancers in check.

Lupin's MEK inhibitors developed as part of its oncology pipeline have shown pre-clinical activity as a single agent as well as in combination. Furthermore, they have also shown early clinical benefit in a small subset of patients. Lupin's Novel Drug Discovery and Development team is focused on building a pipeline of highly differentiated and innovative new chemical entities in the therapeutic areas of oncology, immunology and metabolic disorders. Lupin's NDDD activities were started with the vision to use cutting-edge research in bringing novel molecules that address unmet medical needs in multiple therapeutic areas to market globally.

Lupin will receive an upfront payment of $20 million and potential additional payments for successful achievement of defined clinical, regulatory and commercial milestones for a total deal value of more than $700 million. Additionally, Lu pin will be entitled to receive double-digit roya lties on the sales of the product.

Shares of LUPIN LTD. was last trading in BSE at Rs.733.5 as compared to the previous close of Rs. 740.25. The total number of shares traded during the day was 27442 in over 878 trades.

The stock hit an intraday high of Rs. 745.85 and intraday low of 730.8. The net turnover during the day was Rs. 20268571.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

ICRA updates on ratings of TNPL

Jump Networks Ltd inks agreement to provide wholesale Voip services

Lump Sum Term Key contract for Talcher Fertilizers Limited project awarded

Bajaj Finance Ltd board approves QIP of Rs. 8500 crore

Music Broadcast Ltd. recognized amongst 'India's Best Workplaces for Women - 2019'

ICRA assigns credit ratings to ITD Cementation India Ltd with rating watch

Advani Hotels & Resorts India Ltd Board declares First Interim Dividend of Rs. 0.80 for FY20

GHCL launches 'REKOOP 2.0' - An evolved and expanded expression of its sustainable bedding concept made with forensically tagged recycled polyester

Taneja Aerospace & Aviation Ltd's credit rating upgraded

Sunteck Realty acquires premium project near Lokhandwala, Andheri (West) for mixed-use development

Ahluwalia Contracts India Ltd secures new order of Rs. 407 crores

SMS Lifesciences India Ltd update on news item on Ranitidine HCL

JITF Infralogistics Ltd update on divestment of shares of material subsidiary company

CRISIL updates on ratings of Vivid Global Industries Ltd

Hindalco debuts on Dow Jones Sustainability Index (DJSI) 2019 in the Emerging Markets category

Som Distilleries & Breweries Ltd's subsidiary gets rating upgrade

PMLA Appellate Tribunal also releases assets of 63 moons from ED attachment

NHPC Limited approves debt raising of Rs. 2500 crore

Medicamen Biotech Ltd updates on acquisition of OPAL Pharmaceuticals Pty Ltd

CreditPilot and Tata Communications enter a financial technology partnership

Shares of Westlife Development Limited are now trading on the National Stock Exchange

ICRA revises ratings of UFO Moviez India Ltd

RTS Power Corporation Ltd changes rating agency

CRISIL assigns ratings to NGL Fine-Chem Limited

Tata Power Subsidiary to exit South African JV 'Cennergi' for USD 106 million

BEML and Wipro Infrastructure Engineering in strategic partnership

Ethos Ltd opens new store at Mumbai and closes store at Chandigarh

Glenmark receives Orphan Drug designation for GBR 1342

Asian Paints Ltd arm divests entires stake in Berger Paints Singapore Pte Ltd

CANYON terminates SPA to acquire TRF Ltd's step down subsidiary

Lemon Tree Hotels Ltd signs license agreement for 80 room hotel at Durgapur

Solix expands senior leadership team to accelerate Cloud Growth

Aavas Financiers raises INR 345 crore from IFC through NCDs

Satra Properties India Ltd has sold 49% in subsidiary

Bayer closes Monsanto integration in India

NACL Industries Ltd gets favorable verdict on insurance claim

ICRA credit Rating for Bank facilities of Banswara Syntex Ltd

American Express buys 9 acres land from DLF Group for its Office campus

SML ISUZU Ltd launches 'Executive Lx 5100 XT Bus'

CFO Tech Outlook recognizes Emagia as 'The Top 10 Fintech Solutions Providers 2019'

NBCC India Ltd signs MoU with Utkal University, Bhubaneswar

Central Bank of India changes Average Balance Charges in Savings Accounts on Monthly basis

General Motors and Tata Consultancy Services Launch New Partnership in Global Vehicle Engineering

ICRA downgrades outlook of Sandhar Technologies Ltd

USFDA issues DMF information request to SMS Pharmaceuticals Ltd

Wipro, lndustrie 4.0 Maturity Center Ink Strategic Partnership

Fintech Start-Up Tarrakki launch investment product in association with Reliance Nippon Life AMC

Asian Paints partners with Mahindra Logistics to strengthen its supply chain in Eastern India

Kaveri Seed Company Ltd board to consider buyback on Sep 24, 2019

Calcom Vision Ltd ties up with Bajaj Electricals Ltd







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019